Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 3, 1998, Pages 441-448

  Mousa, Shaker A ^a   Forsythe, Mark ^a   Wityak, John ^a   Bozarth, Jeffrey ^a   Mu, Dun Xue ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Adhesion molecules; Antiplatelet; Antithrombotic; Fibrinogen; GPIIb IIIa; Integrins; Platelet; XR300 XR299

Indexed keywords

2 AMINO 3 [2 [3 (4 FORMAMIDINOPHENYL) 2 ISOXAZOLIN 5 YL]ACETAMIDO]PROPIONIC ACID; 2 AMINO 3 [2 [3 (4 FORMAMIDINOPHENYL) 2 ISOXAZOLIN 5 YL]ACETAMIDO]PROPIONIC ACID ETHYL ESTER; [2 [3 (4 FORMAMIDINOPHENYL)ISOXAZOLIN 5 YL]ACETYL] 2,3 DIAMINOPROPIONATE; [2 [3 (4 FORMAMIDINOPHENYL)ISOXAZOLIN 5 YL]ACETYL] 2,3 DIAMINOPROPIONIC ACID ETHYL ESTER; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; EXTRACELLULAR MATRIX; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBENDOTHELIUM; THROMBOCYTE ACTIVATION; THROMBOSIS;

ADMINISTRATION, ORAL; AMINO ACIDS; ANIMALS; ANTITHROMBINS; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HUMANS; HYDROLYSIS; INFUSIONS, INTRAVENOUS; ISOXAZOLES; KINETICS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0031915559     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199803000-00016     Document Type: Article

References (28)

1. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Platelets Health Dis 1990;4(1):1-26.
2. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985;53:363-73.
3. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9.
4. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985;5:175-84B.
5. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987;10:998-1004.
6. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304:685-91.
7. Rubenstein MD, Wall RT, Bain DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J 1981;102:363-7.
8. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981;48:395-402.
9. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80:198-205.
10. Kruithof EKO, Tran-Thang C, Bachman F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 1986;55:201-5.
11. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GPIIb/IIIa is proximal to the second calcium binding domain of its a subunit. Biol Chem 1990;265:3440-6.
12. Philips DR, Charo IF, Scarborough RM. GPIIb/IIIa: the responsive integrin. Cell 1991;65:359-62.
13. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science 1986;231:1559-62.
14. Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994;19:135-59.
15. Mousa S, Bozarth J, Forsythe M, et al. Antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation 1994;89:3-12.
16. Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J. Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 1992:13(11):413-7.
17. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783-6.
18. Topol EJ, Plow EF. Clinical trials of platelet receptor inhibitors. Thromb Haemost 1993;70(1):94-8.
19. Topol EJ. Novel antithrombotic approaches to coronary artery diseases. Am J Cardiol 1995;75(6):27-33b.
20. Yasuda T, Gold HK, Yaoita H, et al. Comparison effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-22.
21. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK383 (L-700462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88(4 Pt 1):1512-7.
22. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker, Integrelin in elective coronary intervention: IMPACT investigators. Circulation 1995;91(8):2151-7.
23. Kottke-Marchant K, Simpfendorfer C, Lowrie M, Burns D, Anders RJ. Sustained but variable inhibition of platelet aggregation with Xemlofiban, an oral GPIIb/IIIa receptor antagonist, in patients with unstable angina. Circulation 1995;92(8 suppl I:488.
24. Narjes H, Weisenberger H, Muller TH, Deichsel G, Krause J. Tolerability and platelet fibrinogen receptor occupancy (FRO) after oral treatment with BIBU 104 xx in healthy volunteers [Abstract]. Thromb Haemost 1995;73(6):1315-592.
25. Mousa SA, Forsythe M, Lorelli W, et al. Novel nonpeptide antiplatelet GPIIb/IIIa receptor antagonist, DMP754: receptor binding affinity & specificity. Coron Artery Dis 1996;7(10): 767-74.
26. Folts JD, Gallagher K, Rowe GG. Blood flow reduction in stenosed coronary arteries: vasospasm or platelet aggregation? Circulation 1982;65:248-55.
27. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980;17:841-53.
28. Mickelson JK, Simpson PJ, Cronin M, et al. Antiplatelet antibody [7E3 F(ab′)2] prevents rethrombosis after recombinant tissue-plasminogen activator-induced coronary thrombolysis in a canine model. Circulation 1990;81:617-27.